Please assess the completion status of the following clinical trial:

Trial Title: Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed intermediate- or high-grade malignant soft tissue sarcoma~  * Advanced and/or metastatic disease~ * Previously untreated disease~* The following tumor types are not allowed:~  * Well-differentiated liposarcoma~ * Embryonal rhabdomyosarcoma~ * Chondrosarcoma (excluding extraskeletal myxoid chondrosarcoma)~ * Osteosarcoma (excluding extraskeletal osteosarcoma)~ * Ewing tumors/primitive neuroectodermal tumor (PNET)~ * Gastrointestinal stromal tumors (GIST)~ * Dermatofibrosarcoma protuberans~* Must have confirmed disease progression based on investigator's judgment prior to study enrollment~* Measurable disease according to RECIST v 1.1 criteria~  * Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, are usually not considered measurable unless there has been demonstrated progression in the lesion~* Formalin fixed paraffin embedded tumor blocks or representative hematoxylin/eosin slides (preferably both) available (local histopathological diagnosis will be accepted for trial entry)~* No prior anticancer therapy for this disease~  * No prior anthracycline~ * Non-anthracycline therapy for nonmetastatic disease is acceptable~* No known history of CNS metastases or leptomeningeal tumor spread~PATIENT CHARACTERISTICS:~* WHO performance status 0-1~* Absolute neutrophil count ≥ 1.5 x 10\^9/L~* Hemoglobin ≥ 9 g/dL~* Platelet count ≥ 100 x 10\^9/L~* Bilirubin normal~* ALT/AST ≤ 2.5 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 2.5 times ULN, (if alkaline phosphatase \> 2.5 times ULN, hepatic isoenzymes 5-nucleotidase and/or GGT must be within the normal range)~* Albumin \> 30 g/L~* Serum creatinine ≤ 1.5 times ULN~* Creatinine clearance ≥ 30 mL/min~* Creatine phosphokinase (CPK) ≤ 2.5 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception (double barrier method for men) 2 weeks prior to, during, and for 3 months (women) or 5 months (men) after completion of study therapy~* LVEF normal by MUGA scan or ECHO~* 12-lead ECG normal (without clinically significant abnormalities)~* None of the following unstable cardiac conditions:~  * Congestive heart failure~ * Angina pectoris~ * Myocardial infarction within the past year~ * Uncontrolled arterial hypertension, defined as BP ≥ 150/100 mm Hg despite optimal medical therapy~ * Clinically significant arrhythmias~* No active or uncontrolled infections or serious illnesses or medical conditions, including a history of any of the following:~  * Chronic alcohol abuse~ * Hepatitis~ * HIV~ * Cirrhosis~* No history of malignancy within the past 5 years, except soft tissue sarcoma, basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, resected incidental prostate cancer (staged pT2 with Gleason score ≤ 6 and postoperative PSA \< 0.5 ng/mL)~  * Patients with any history of malignancies who are disease-free for more than 5 years are eligible~* a history of malignancy and disease-free for more than 5 years~* No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule~* No concurrent alcohol consumption~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* At least 28 days since prior and no concurrent anticancer therapy including systemic therapy, radiotherapy, or surgery~* At least 28 days since prior and no other concurrent investigational agents~* No concurrent phenytoin, live attenuated vaccines, or yellow fever vaccine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Doxorubicin 75 mg/m² every 3 weeks (Type: ACTIVE_COMPARATOR): Doxorubicin administered on day 1 every 3 weeks for a maximum of 6 cycles
- Trabectedin IV 3 hours (Type: EXPERIMENTAL): Trabectedin administered on day 1 every 3 weeks at the dose of 1.3 mg/m² until progression
- Trabectedin IV 24 hours every 3 weeks (Type: EXPERIMENTAL): Trabectedin administered on day 1 every 3 weeks at the dose of 1.5 mg/m² over 24 hours until progression

Based on this trial design, predict the completion outcome and termination type (if applicable).